Faron Pharmaceuticals Oy (LON:FARN) Reaches New 12-Month Low at $120.00

Faron Pharmaceuticals Oy (LON:FARNGet Free Report)’s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 120 ($1.52) and last traded at GBX 127.50 ($1.61), with a volume of 37642 shares trading hands. The stock had previously closed at GBX 132.50 ($1.68).

Faron Pharmaceuticals Oy Trading Down 3.1 %

The firm’s 50 day moving average is GBX 171.59 and its 200 day moving average is GBX 251.22. The company has a market cap of £85.01 million, a PE ratio of -294.17 and a beta of -0.14. The company has a debt-to-equity ratio of 121.51, a current ratio of 0.59 and a quick ratio of 1.09.

Faron Pharmaceuticals Oy Company Profile

(Get Free Report)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.

Featured Stories

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.